David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.2B |
| 2 |
NVIDIA
NVDA
|
+$1.02B |
| 3 |
T-Mobile US
TMUS
|
+$911M |
| 4 |
Netflix
NFLX
|
+$699M |
| 5 |
Micron Technology
MU
|
+$672M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$768M |
| 2 |
Robinhood
HOOD
|
+$643M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$534M |
| 4 |
Microsoft
MSFT
|
+$493M |
| 5 |
Intuit
INTU
|
+$472M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.33% |
| 2 | Healthcare | 8.66% |
| 3 | Consumer Discretionary | 8.33% |
| 4 | Financials | 6.44% |
| 5 | Industrials | 6.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3251
International Paper
IP
$21.7B
| $818K | ﹤0.01% |
17,467
-1,207,479
| -99% | -$57.1M |
|
3252
Krispy Kreme
DNUT
$618M
| $818K | ﹤0.01% |
281,038
+64,973
| +30% | +$227K |
|
3253
Mesa Laboratories
MLAB
$713M
| $816K | ﹤0.01% |
+8,665
| New | +$951K |
|
3254
CALL
Macy's
M
$5.94B
| $816K | ﹤0.01% |
70,000
| – | – |
|
3255
Ligand Pharmaceuticals
LGND
$5.62B
| $813K | ﹤0.01% |
+7,151
| New | +$764K |
|
3256
Kura Oncology
KURA
$1.21B
| $812K | ﹤0.01% |
140,713
-278,275
| -66% | -$1.7M |
|
3257
Build-A-Bear
BBW
$494M
| $810K | ﹤0.01% |
15,719
-13,881
| -47% | -$588K |
|
|
SEE
3258
DELISTED
Sealed Air
SEE
| $804K | ﹤0.01% |
+25,926
| New | +$771K |
|
3259
Descartes Systems
DSGX
$6.64B
| $803K | ﹤0.01% |
7,900
+1,300
| +20% | +$137K |
|
3260
iShares Russell 2500 ETF
SMMD
$3.82B
| $803K | ﹤0.01% |
11,853
| – | – |
|
3261
PUT
Northern Oil and Gas
NOG
$2.82B
| $802K | ﹤0.01% |
28,300
-31,400
| -53% | -$845K |
|
3262
Synaptics
SYNA
$3.71B
| $802K | ﹤0.01% |
12,375
-37,940
| -75% | -$2.23M |
|
3263
PUT
Helmerich & Payne
HP
$4.21B
| $802K | ﹤0.01% |
52,900
+39,300
| +289% | +$720K |
|
3264
Praxis Precision Medicines
PRAX
$10.3B
| $801K | ﹤0.01% |
19,056
+6,848
| +56% | +$261K |
|
3265
Lattice Semiconductor
LSCC
$16.5B
| $801K | ﹤0.01% |
16,349
+9,398
| +135% | +$450K |
|
3266
CALL
Cogent Communications
CCOI
$506M
| $800K | ﹤0.01% |
+16,600
| New | +$843K |
|
3267
Gorman-Rupp
GRC
$2.03B
| $800K | ﹤0.01% |
21,790
+10,030
| +85% | +$361K |
|
3268
Centuri Holdings
CTRI
$2.1B
| $800K | ﹤0.01% |
+35,648
| New | +$697K |
|
3269
Akebia Therapeutics
AKBA
$266M
| $797K | ﹤0.01% |
219,089
+145,928
| +199% | +$401K |
|
|
BKHA
3270
Black Hawk Acquisition Corp
BKHA
$49.4M
| $797K | ﹤0.01% |
75,000
| – | – |
|
3271
CALL
RXO
RXO
$3.56B
| $797K | ﹤0.01% |
+50,700
| New | +$769K |
|
3272
Bio-Rad Laboratories Class A
BIO
$10.4B
| $796K | ﹤0.01% |
3,300
-15,625
| -83% | -$3.69M |
|
3273
iShares JPMorgan EM Corporate Bond ETF
CEMB
$436M
| $794K | ﹤0.01% |
+17,471
| New | +$780K |
|
|
NPKI
3274
NPK International
NPKI
$1.12B
| $793K | ﹤0.01% |
93,220
+10,461
| +13% | +$76.7K |
|
3275
Madison Square Garden
MSGS
$9.8B
| $793K | ﹤0.01% |
3,796
-25,484
| -87% | -$4.91M |
|
Similar funds
David Shaw's Q2 2025 Portfolio in Review
As of Q2 2025, David Shaw held 4,838 positions worth $141B, up 26% from $112B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
David Shaw deployed $7.51B of net new capital in Q2 2025, opening 647 new positions and adding to 1,556 existing holdings. Its largest new stake was Sea Limited: 1,365,221 shares worth $218M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was GE Vernova, an estimated $768M trimmed.
- David Shaw's largest Q2 2025 buy was Sea Limited: 1,365,221 shares worth $218M.
- David Shaw added most to Apple in Q2 2025, an estimated $1.2B increase.
- David Shaw's biggest Q2 2025 reduction was GE Vernova, cutting an estimated $768M.
- David Shaw fully exited Novo Nordisk in Q2 2025, selling an estimated $176M.
- David Shaw's ten largest holdings make up 12% of its $141B portfolio in Q2 2025.
- David Shaw opened 647 new positions and closed 532 in Q2 2025.
- David Shaw's portfolio value rose 26% quarter-over-quarter to $141B.
Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.